Details

Autor(en) / Beteiligte

• Lyke, Kirsten E.
• Atmar, Robert L.
• Islas, Clara Dominguez
• Posavad, Christine M.
• Szydlo, Daniel
• PaulChourdhury, Rahul
• Deming, Meagan E.
• Eaton, Amanda
• Jackson, Lisa A.
• Branche, Angela R.
• El Sahly, Hana M.
• Rostad, Christina A.
• Martin, Judith M.
• Johnston, Christine
• Rupp, Richard E.
• Mulligan, Mark J.
• Brady, Rebecca C.
• Frenck, Robert W.
• Bäcker, Martín
• Kottkamp, Angelica C.
• Babu, Tara M.
• Rajakumar, Kumaravel
• Edupuganti, Srilatha
• Dobrzynski, David
• Coler, Rhea N.
• Archer, Janet I.
• Crandon, Sonja
• Zemanek, Jillian A.
• Brown, Elizabeth R.
• Neuzil, Kathleen M.
• Stephens, David S.
• Post, Diane J.
• Nayak, Seema U.
• Suthar, Mehul S.
• Roberts, Paul C.
• Beigel, John H.
• Montefiori, David C.

Titel

Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant

Ist Teil von

• Cell reports. Medicine, 2022-07, Vol.3 (7), p.100679, Article 100679

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• The Omicron variant of SARS-CoV-2 exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to generate protective immunity. We assess the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. All prime-boost combinations substantially increase the neutralization titers to Omicron although the boosted titers decline rapidly within 2 months from the peak response compared to boosted titers against the prototypic D614G variant. Boosted Omicron neutralization titers are substantially higher for homologous mRNA vaccine boosting, and for heterologous mRNA and Ad26.COV2.S vaccine boosting, compared to homologous Ad26.COV2.S boosting. Homologous mRNA vaccine boosting generates nearly equivalent neutralizing activity against Omicron sublineages BA.1, BA.2, and BA.3 but modestly reduced neutralizing activity against BA.2.12.1 and BA.4/BA.5 compared to BA.1. These results have implications for boosting requirements to protect against Omicron and future variants of SARS-CoV-2. This trial was conducted under ClincalTrial.gov# NCT04889209. [Display omitted] •Vaccine boost substantially increases Omicron neutralizing antibody titers•Boosted neutralization titers to Omicron but not prototypic D614G decline rapidly•Ad26.COV2.S is better as prime or boost with mRNA vaccines than as homologous boost•Omicron sublineages exhibit 5-12 times reduced neutralization by mRNA-1273 boost sera Following COVID-19 vaccine prime and boost, Lyke et al. find higher Omicron neutralization titers for homologous mRNA boost and heterologous mRNA and Ad26.COV2.S boost, compared to homologous Ad26.COV2.S boost. Omicron titers rapidly decline by Day 91 compared to prototypic D614G. Moderate differences in neutralization (<3-fold) was noted among Omicron sublineages.